Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Extends Use of Compugen s Genecarta Database

NEW YORK, Feb. 18 (GenomeWeb News) - Abbott Laboratories will continue to use Compugen's Genecarta technology for analyzing novel drug targets, Compugen said today.

 

Under the extended agreement, which started in early 2003, Abbott will receive several updates of Compugen's Genecarta database.

 

Genecarta, a genome, transcriptome, and proteome database with a graphical user interface and query tools, is based on Tel Aviv-based Compugen's Leads platform to publicly available genomic and gene expression data.

 

The Scan

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.